Virtu Financial LLC Acquires 222,761 Shares of Pfizer Inc. $PFE

Virtu Financial LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 87.5% in the 4th quarter, Holdings Channel reports. The firm owned 477,207 shares of the biopharmaceutical company’s stock after acquiring an additional 222,761 shares during the period. Pfizer comprises 0.5% of Virtu Financial LLC’s investment portfolio, making the stock its 12th largest holding. Virtu Financial LLC’s holdings in Pfizer were worth $11,882,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its position in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC grew its position in Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer announced that Chief Financial Officer Dave Denton will step down on August 15 for an external opportunity, prompting concerns about leadership continuity and execution at a time when investors are closely watching the company’s 2026 outlook. Reuters article
• Negative Sentiment: The market appears to be treating the CFO transition as a near-term uncertainty, with several reports noting that Pfizer’s shares fell as investors reassessed growth catalysts and financial stability. TipRanks article
• Neutral Sentiment: Pfizer named Cecile Guegan as interim CFO and said it is conducting a comprehensive search for a permanent replacement, which helps reduce uncertainty but does not fully remove investor concerns. Business Wire article
• Neutral Sentiment: The company reaffirmed its full-year 2026 guidance, which should limit downside if management can maintain operational momentum despite the executive transition. TipRanks article
• Positive Sentiment: Recent business updates, including progress on the obesity pipeline and a China partnership expansion, provide longer-term growth optionality, though they were not enough to offset today’s leadership-driven selloff. Yahoo Finance article

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. UBS Group reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Monday, March 2nd. HSBC raised their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Finally, Guggenheim boosted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.82.

Pfizer Price Performance

Shares of Pfizer stock opened at $25.25 on Friday. The company’s fifty day simple moving average is $26.26 and its two-hundred day simple moving average is $26.33. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The firm has a market cap of $143.94 billion, a PE ratio of 19.28 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the firm earned $0.92 earnings per share. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.